Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

78.60 -8.57 (-9.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Evaluating Guardant Health: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening ↗
FDA panel recommends approval for Guardant Health's Shield blood test for colorectal cancer screening. 
Via Benzinga
News headline image
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test ↗
The companies are likely to soon battle it out in the colon cancer screening market. 
Via Investor's Business Daily
News headline image
Key Takeaways From Guardant Health Analyst Ratings ↗
 
Via Benzinga
News headline image
Analyst Expectations For Guardant Health's Future ↗
 
Via Benzinga
News headline image
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday? ↗
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC... 
Via Benzinga
News headline image
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
From Guardant Health, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q1 2024 ↗
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
From Guardant Health, Inc.
Via Business Wire
News headline image
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
News headline image
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales ↗
The companies are working to detect colon cancer and precancerous markers in blood and/or stool. 
Via Investor's Business Daily
News headline image
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks. ↗
These stocks are solid buys according to the advanced AI model Claude 3, which has been touted as potentially superior to ChatGPT. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat... 
Via Benzinga
News headline image
Insiders Buying Advance Auto Parts And 2 Other Stocks ↗
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.